Role of N-Acetylcysteine in the treatment of Acute Respiratory Disorders 41. Poole PJ, Black PN. Oral mucolytic drugs for exacerbations of chronic obstructive pulmonary disease: systematic review. BMJ 2001; 322: 1271-4 42. Brocard H, Charpin J, Germouty J. Etude multi-centrique en double aveugle avec acetylcysteine orale vs placebo. Eur J Respir Dis 1980; 61 Suppl. 111: 65-9 43. Verstraeten JM. Mucolytic treatment in chronic obstructive pulmonary disease: double-blind comparative clinical trial with N-acetylcysteine, bromhexine and placebo. Acta Tuberc Pneumol Belg 1979: 70 (1): 71-80 44. Lemy-Debois N, Frigerio G, Lualdi P. Oral acetylcysteine in bronchopulmonary disease: comparative trial with bromhexine. Acta Ther 1978; 4: 125-32 45. Nikolic’ P, Korac’ D. The influence of acetylcysteine on respiratory functions in children with recurrent bronchitis. Eur J Respir Dis 1980; 61 Suppl. 111: 141 46. Ribeiro TM, Cunha LGT, Santos M, et al. Treatment of bronchial diseases in pediatrics: results of the use of oral acetylcysteine in 80 cases. Eur J Respir Dis 1980; 61 Suppl. 111: 136-8 47. Biscatti G, Bruschelli M, Damonte G, et al. Ricerca controllata sugli effetti clinici dell'acetilcisteina per via orale nelle affexzioni respiratorie in pediatria. Minerva Pediatr 1972; 24: 1075-84 48. Hofman A. Oral acetylcysteine in the treatment of bronchial asthma and diseases of the upper airways. Eur J Respir Dis 1980; 61 Suppl. 111: 139 49. Simon LM, Suttorp N. Lung cell oxidant injury: decrease in oxidant mediated cytotoxicity by N-acetylcysteine. Eur J Respir Dis 1985; 66 Suppl. 139: 132-5 50. Voisin C, Aerts C, Wallaert B. Prevention of in vitro oxidant-mediated alveolar macrophage injury by cellular glutathione and precursors. Bull Eur Physiopathol Respir 1987; 23: 309-13 51. Moldeus P, Berggren M, Grafström R. N-Acetylcysteine protection against the toxicity of cigarette smoke and cigarette smoke condensates in various tissues and cells in vitro. Eur J Respir Dis 1985; 66 Suppl. 139: 123-9 52. Green GM. Pharmacoprevention of tobacco smoke effects on macrophage cells. Eur J Respir Dis 1985; 66 Suppl. 139: 113-6 53. Bergstrand H, Bjornson A, Eklund A, et al. Stimuli-induced superoxide radical generation in vitro by human alveolar macrophages from smokers: modulation by N-acetylcysteine treatment in vivo. J Free Radic Biol Med 1986; 2 (2): 119-27 54. Jeffery PK, Rogers DF, Ayers MM. Effect of oral acetylcysteine on tobacco smoke-induced secretory cell hyperplasia. Eur J Respir Dis 1985; 66 Suppl. 139: 117-22 55. Sprince H. Protective action of sulfur compounds against aldehyde toxicants of cigarette smoke. Eur J Respir Dis 1985; 66 Suppl. 139: 102-12 56. Rubio ML, Sanchez-Cifuentes MV, Ortega M, et al. N-acetylcysteine prevents cigarette smoke induced small alterations in rats. Eur Respir J 2000; 15: 505-11 57. Rhoden CR, Lawrence J, Godleski JJ, et al. N-Acetylcysteine prevents lung inflammation after short-term inhalation exposure to concentrated ambient particles. Toxicol Sci 2004; 79 (2): 296-303 58. Xu L, Cai BQ, Zhu YJ. Pathogenesis of cigarette smoke-induced chronic obstructive pulmonary disease and therapeutic effects of glucocorticoids and N-acetylcysteine in rats. Chin Med J (Engl) 2004; 117: 1611-9 59. Eklund A, Eriksson Ö, Håkansson L, et al. Oral N-acetylcysteine reduces selected humoral markers of inflammatory cell activity in BAL fluid from healthy smokers: correlation to effects on cellular variables. Eur Respir J 1988; 1 (9): 832-8 60. Linden M, Wieslander E, Eklund A, et al. Effects of oral N-acetylcysteine on cell content and macrophage function in bronchoalveolar lavage from healthy smokers. Eur Respir J 1988; 1 (7): 645-50 61. Bernard GR, Lucht WD, Niedermeyer ME, et al. Effect of N- acetylcysteine on the pulmonary response to endotoxin in the awake sheep and upon in vitro granulocyte function. J Clin Invest 1984; 73 (6): 1772-84 62. Wuyts, WA, Vanaudenaerde BM, Dupont LJ. N-acetylcysteine reduces chemokine release via inhibition of p38 MAPK in human airway smooth muscle cells. Eur Respir J 2003; 22: 43-9 63. Mayer M, Noble M. N-Acetyl-L-cysteine is a pluripotent protector against cell death and enhancer of trophic factor-mediated cell survival in vitro. Proc Natl Acad Sci 1994 Aug; 90: 7496-500 64. Lucht WD, English DK, Bernard GR. Prevention of release of granulocyte aggregants into sheep lung lymph following endotoxemia by N- acetylcysteine. Am J Med Sci 1987; 294 (3): 161-7 65. Puerto M, Guayerbas N, Víctor VM, et al. Effects of N-acetylcysteine on macrophage and lymphocyte functions in a mouse model of premature ageing. Pharmacol Biochem Behav 2002; 73 (4): 797-804 66. Schmid G, Li Bianci E, Straface E, et al. N-acetylcysteine (NAC) counteracts erythrocyte damage and is useful in the management of COPD [abstract no. 910271]. Am J Respir Crit Care Med 2002; 165: A227 67. Sadowska AM, van Overveld FJ, Górecka D, et al. The interrelationship between markers of inflammation and oxidative stress in chronic obstructive pulmonary disease: modulation by inhaled steroids and antioxidant. Respir Med 2005; 99 (2): 241-9 68. Zuin R, Palamidese A, Negrin R, et al. High-dose N-acetylcysteine in patients with chronic obstructive pulmonary disease exacerbations. Clin Drug Invest 2005; 25(6): 401-8 69. Victor VM, De La Fuente M. N-acetylcysteine improves in vitro the function of macrophages from mice with endotoxin-induced oxidative stress. Free Radic Res 2002; 36 (1): 33-45 70. De la Fuente M, Victor VM. Ascorbic acid and N-acetylcysteine improve in vitro the function of lymphocytes from mice with endotoxin-induced oxidative stress. Free Radic Res 2001; 35 (1): 73-84 71. Venketaraman V, Dayaram YK, Amin AG, et al. Role of glutathione in macrophage control of mycobacteria. Infect Immun 2003; 71(4): 1864-71 72. De Flora S, Grassi C, Carati L. Attenuation of influenza-like symptomatology and improvement of cell-mediated immunity with long-term N-acetylcysteine treatment. Eur Respir J 1997; 10 (7): 1535-41 73. Arranz Salas L, Fernandez C, Rodriguez A, et al. Efecto de un tratamiento de 2 meses con N-acetilcisteína sobre la función de neutrofilos en mujeres mayores de 50 anos. Rev Esp Geriatr Gerontol 2005; 40 Suppl: 63-118 [129] 74. Ferrari V. Safety and drug interactions of oral acetylcysteine related to utilization data. Eur J Respir Dis 1980; 61 Suppl. 111: 151-7 75. Aquilani, R, Ferraris L, Majani U, et al. Studio clinico sull’efficacia terapeutica e la tollerabilità dell’acetilcisteina per via orale in un’unica somministrazione al giorno (Fluimucil 600) nel trattamento delle broncopneuomopatie. Clin Ther 1985; 144: 495-503 76. Marini U, Visconti G, Spotti D, et al. Controlled endoscopic study on gastrointestinal safety of acetylcysteine after oral administration. Eur J Respir Dis 1980; 61 Suppl. 111: 147-50 27
Cod. X000XXX00 Depositato presso l’Agenzia Italiana del Farmaco in data 00 xxxxxxxxxxxxx 0000
Change language